FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2997339635> ?p ?o ?g. }

• W2997339635 endingPage "e0226552" @default.
• W2997339635 startingPage "e0226552" @default.
• W2997339635 abstract "Background Imatinib mesylate (IM) is a first-line treatment option for patients with chronic myeloid leukemia (CML). Patients who fail or are intolerant to IM therapy are treated with more expensive second and third-generation tyrosine kinase inhibitors. Patients show wide variation in trough concentrations in response to standard dosing. Thus, many patients receive subtherapeutic or supratherapeutic doses. Therapeutic drug monitoring (TDM) may improve dose management that, in turn, may reduce costs and improve outcomes. However, TDM also adds to the cost of patient care. The objective of this study was to determine the cost-effectiveness of TDM for generic IM therapy. Methods We developed a microsimulation model for the trough plasma concentration of IM which is related to a cytogenetic or molecular response. We compared two cohorts: one with TDM and one without TDM (NTDM). The lifetime incremental cost-effectiveness ratio (ICER) was calculated using quality-adjusted life years (QALYs) as the effectiveness measure. One-way and probabilistic sensitivity analyses were performed. Results The lifetime cost and QALY of treatment with TDM were $2,137K [95% Ci: 2,079K; 2,174K] and 12.37 [95% CI: 12.07; 12.55], respectively. The cost and QALY of NTDM were $2,132K [95% CI: 2,091K; 2,197K] and 12.23 [95% CI: 11.96; 12.50], respectively. The incremental cost and QALY for TDM relative to NTDM was $4,417 [95% CI: -52,582; 32,097]) and 0.15 [95% CI: -0.13; 0.28]. The ICER for TDM relative to NTDM was $30,450/QALY. Probabilistic sensitivity analysis showed that TDM was cost-effective relative to NTDM in 90% of the tested scenarios at a willingness-to-pay threshold of $100,000/QALY. Conclusions Although the impact of TDM is modest, the cost-effectiveness over a lifetime horizon (societal perspective, ($30,450/QALY) falls within the acceptable range (< $100k/QALY)." @default.
• W2997339635 created "2020-01-10" @default.
• W2997339635 creator A5008575713 @default.
• W2997339635 creator A5022854192 @default.
• W2997339635 creator A5027431995 @default.
• W2997339635 creator A5032255317 @default.
• W2997339635 creator A5044119496 @default.
• W2997339635 creator A5084151216 @default.
• W2997339635 date "2019-12-23" @default.
• W2997339635 modified "2023-10-11" @default.
• W2997339635 title "Cost effectiveness of therapeutic drug monitoring for imatinib administration in chronic myeloid leukemia" @default.
• W2997339635 cites W1887153209 @default.
• W2997339635 cites W1944560152 @default.
• W2997339635 cites W1968747503 @default.
• W2997339635 cites W1988837929 @default.
• W2997339635 cites W1993702149 @default.
• W2997339635 cites W2000182266 @default.
• W2997339635 cites W2004492241 @default.
• W2997339635 cites W2022260454 @default.
• W2997339635 cites W2028959752 @default.
• W2997339635 cites W2029998230 @default.
• W2997339635 cites W2042188232 @default.
• W2997339635 cites W2045194073 @default.
• W2997339635 cites W2046370192 @default.
• W2997339635 cites W2053131280 @default.
• W2997339635 cites W2055198551 @default.
• W2997339635 cites W2055515709 @default.
• W2997339635 cites W2057827171 @default.
• W2997339635 cites W2064367288 @default.
• W2997339635 cites W2065711601 @default.
• W2997339635 cites W2074015360 @default.
• W2997339635 cites W2083749767 @default.
• W2997339635 cites W2085255253 @default.
• W2997339635 cites W2088110670 @default.
• W2997339635 cites W2090092477 @default.
• W2997339635 cites W2092508198 @default.
• W2997339635 cites W2097799776 @default.
• W2997339635 cites W2104835016 @default.
• W2997339635 cites W2107268345 @default.
• W2997339635 cites W2117697495 @default.
• W2997339635 cites W2134883702 @default.
• W2997339635 cites W2137016351 @default.
• W2997339635 cites W2140134889 @default.
• W2997339635 cites W2143939343 @default.
• W2997339635 cites W2147109509 @default.
• W2997339635 cites W2150604072 @default.
• W2997339635 cites W2162139090 @default.
• W2997339635 cites W2165831721 @default.
• W2997339635 cites W2166270808 @default.
• W2997339635 cites W2167325977 @default.
• W2997339635 cites W2171722798 @default.
• W2997339635 cites W2172189430 @default.
• W2997339635 cites W2180873921 @default.
• W2997339635 cites W2266168940 @default.
• W2997339635 cites W2291265461 @default.
• W2997339635 cites W2313607879 @default.
• W2997339635 cites W2326589717 @default.
• W2997339635 cites W2397234997 @default.
• W2997339635 cites W2469022727 @default.
• W2997339635 cites W2513126620 @default.
• W2997339635 cites W2552508548 @default.
• W2997339635 cites W2592060299 @default.
• W2997339635 cites W2736298805 @default.
• W2997339635 cites W2755201909 @default.
• W2997339635 cites W2759146932 @default.
• W2997339635 cites W2766187515 @default.
• W2997339635 cites W2780178948 @default.
• W2997339635 cites W2900357627 @default.
• W2997339635 cites W2948787811 @default.
• W2997339635 doi "https://doi.org/10.1371/journal.pone.0226552" @default.
• W2997339635 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6927594" @default.
• W2997339635 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31869360" @default.
• W2997339635 hasPublicationYear "2019" @default.
• W2997339635 type Work @default.
• W2997339635 sameAs 2997339635 @default.
• W2997339635 citedByCount "9" @default.
• W2997339635 countsByYear W29973396352020 @default.
• W2997339635 countsByYear W29973396352021 @default.
• W2997339635 countsByYear W29973396352022 @default.
• W2997339635 countsByYear W29973396352023 @default.
• W2997339635 crossrefType "journal-article" @default.
• W2997339635 hasAuthorship W2997339635A5008575713 @default.
• W2997339635 hasAuthorship W2997339635A5022854192 @default.
• W2997339635 hasAuthorship W2997339635A5027431995 @default.
• W2997339635 hasAuthorship W2997339635A5032255317 @default.
• W2997339635 hasAuthorship W2997339635A5044119496 @default.
• W2997339635 hasAuthorship W2997339635A5084151216 @default.
• W2997339635 hasBestOaLocation W29973396351 @default.
• W2997339635 hasConcept C112705442 @default.
• W2997339635 hasConcept C112930515 @default.
• W2997339635 hasConcept C126322002 @default.
• W2997339635 hasConcept C143998085 @default.
• W2997339635 hasConcept C2777288759 @default.
• W2997339635 hasConcept C2777583451 @default.
• W2997339635 hasConcept C2778729363 @default.
• W2997339635 hasConcept C2780272996 @default.
• W2997339635 hasConcept C2909675724 @default.
• W2997339635 hasConcept C2911091166 @default.

• next